AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CYNATA THERAPEUTICS LTD

0.385

+0.0051.32%

Volume:567.78K

Turnover:223.95K

Market Cap:91.42M

PE:-8.40

High:0.410

Open:0.380

Low:0.380

Close:0.380

52wk High:0.435

52wk Low:0.140

Shares:237.45M

Float Shares:175.62M

Volume Ratio:2.63

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.046

EPS(LYR):-0.046

ROE:-142.29%

ROA:-77.08%

PB:15.28

PE(LYR):-8.40

Loading ...

Overview Company News Filings

ASX Opportunities: Aroa Biosurgery And 2 Other Promising Penny Stocks

Simply Wall St.

Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says

MT Newswires Live

BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses

Cynata Completes Patient Enrolment in Phase 2 aGvHD Trial

Patient Enrolment Completed in Phase 2 Agvhd Clinical Trial

THOMSON REUTERS

Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%

MT Newswires Live

Cynata Therapeutics Completes Phase 3 SCUIpTOR Trial in Knee Osteoarthritis; Shares Up 6%

MT Newswires Live

ASX Stock Picks With Estimated Discounts Of Up To 39.1%

Simply Wall St.

Cynata Therapeutics Ltd-Cynata Receives $1.7M R&D Tax Incentive Refund

THOMSON REUTERS

Cynata Therapeutics' Three Active Programs Expected to Deliver 'Major' Catalysts Over Next Quarters, Says Euroz Hartleys

MT Newswires Live

Cynata Therapeutics Ltd-September 2025 Quarterly Activity Report and Appendix 4C

THOMSON REUTERS

When Will Cynata Therapeutics Limited (ASX:CYP) Turn A Profit?

Simply Wall St.

3 ASX Stocks That May Be Trading Below Estimated Value In October 2025

Simply Wall St.

ASX Stocks Priced Below Intrinsic Value Estimates Include Guzman y Gomez And Two More

Simply Wall St.

ASX Value Insights Duratec And Two More Stocks Possibly Below Fair Value

Simply Wall St.

ASX Insights On Electro Optic Systems Holdings And 2 Other Stocks Priced Below Estimated Value

Simply Wall St.

ASX Value Stock Estimates Offering Opportunities In October 2025

Simply Wall St.

ASX Stocks That May Be Undervalued In October 2025

Simply Wall St.

BRIEF-Cynata Therapeutics Enters At-Market Subscription Agreement With Acuity Capital

Cynata Therapeutics Ltd - Entered Into an at--Market Subscription Agreement With Acuity Capital

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYP.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","market":"AU","secType":"STK","nameCN":"CYNATA THERAPEUTICS LTD","latestPrice":0.385,"timestamp":1770700320000,"preClose":0.38,"halted":0,"volume":567779,"delay":0,"changeRate":0.013157894736842117,"nameEN":"CYNATA THERAPEUTICS LTD","floatShares":175624818,"shares":237454369,"eps":-0.045818,"marketStatus":"Not Yet Opened","change":0.005,"latestTime":"02-10 16:12:00 AEDT","open":0.38,"high":0.41,"low":0.38,"amount":223954,"amplitude":0.078947,"askPrice":0.4,"askSize":25338,"bidPrice":0.38,"bidSize":16216,"shortable":3,"etf":0,"ttmEps":-0.045818,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.38,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":2.626109,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CYP.AU\",,,,,undefined,":{"symbol":"CYP.AU","floatShares":175624818,"roa":"-77.08%","roe":"-142.29%","lyrEps":-0.045818,"volumeRatio":2.626109,"shares":237454369,"dividePrice":0,"high":0.41,"amplitude":0.078947,"preClose":0.38,"low":0.38,"week52Low":0.14,"pbRate":"15.28","psRate":"48.50","week52High":0.435,"institutionHeld":0,"latestPrice":0.385,"committee":-0.219522,"eps":-0.045818,"divideRate":0,"volume":567779,"delay":0,"ttmEps":-0.045818,"open":0.38,"prevYearClose":0.345,"prevWeekClose":0.345,"prevMonthClose":0.32,"prevQuarterClose":0.345,"fiveDayClose":0.335,"twentyDayClose":0.375,"sixtyDayClose":0.25,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYP.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-12-15","symbol":"CYP.AU","defaultRemindTime":1607986800000,"type":"split","dateTimestamp":1607950800000,"forFactor":2147483647,"toFactor":2147483647,"ratio":0.997023}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYP.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610505033","title":"ASX Opportunities: Aroa Biosurgery And 2 Other Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2610505033","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610505033?lang=en_us&edition=fundamental","pubTime":"2026-02-09 03:02","pubTimestamp":1770577340,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a challenging period, with a significant downturn influenced by global market pressures and recent tech selloffs. Despite the turbulence, investors often seek opportunities in penny stocks, which can offer unique value propositions when backed by strong financials. These smaller or newer companies may present potential for growth and stability, making them intriguing options for those looking to uncover hidden gems in the stock market.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/asx-opportunities-aroa-biosurgery-and-2-other-promising-penn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/asx-opportunities-aroa-biosurgery-and-2-other-promising-penn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BVR.AU","MTO.AU","BK7077","BK7055","IGL.AU","ARX.AU","BK7128","BK7050","WAF.AU","BK7104","BK7508","BK7501","BK7503","BK7062","BK7016","BK7095","BK7506","AAL.AU","MXI.AU","VRS.AU","SSM.AU","PPS.AU","DSK.AU","AEF.AU","BK7067","BK7143","CYP.AU","BK7045"],"gpt_icon":0},{"id":"2591967429","title":"Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591967429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591967429?lang=en_us&edition=fundamental","pubTime":"2025-12-16 11:12","pubTimestamp":1765854732,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clin","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4218","BK4539","BK4181","HST","LENZ","BK4588","BK7508","BK4139","CYP.AU","BK4007","BK7067","BK4585","BK7501"],"gpt_icon":0},{"id":"2591694216","title":"BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2591694216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591694216?lang=en_us&edition=fundamental","pubTime":"2025-12-15 12:11","pubTimestamp":1765771917,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cynata Therapeutics leaps as clinical trial progresses** Shares of Cynata Therapeutics CYP.AX rise as much as 7.6% to A$0.285, their highest level since December 1** Stock set for its strongest trading session in over a week, if current trends hold** Stem cell and regenerative medicine maker says 65 patients have been enrolled in its Phase 2 clinical trial of CYP-001 in adults diagnosed with acute graft versus host disease ** aGvHD is a life-threatening complication where donor’s immune cells attack recipient's tissues ** Co says CYP-001 is designed to modulate immune system and improve both response rates and survival outcomes in aGvHD** Stock up 18.6% YTD, including session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL086:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","CYP.AU","BK7508"],"gpt_icon":0},{"id":"2591594698","title":"Cynata Completes Patient Enrolment in Phase 2 aGvHD Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591594698","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591594698?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:22","pubTimestamp":1765758165,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics Ltd. has announced the completion of patient enrolment in its Phase 2 clinical trial of CYP-001 for the treatment of acute graft versus host disease . The trial has enrolled 65 participants across the US, Europe, and Australia, who were randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary evaluation period will conclude in March 2026, with results expected in June 2026. The results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cynata Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3xwf7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYP.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2591698590","title":"Patient Enrolment Completed in Phase 2 Agvhd Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591698590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591698590?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:22","pubTimestamp":1765758150,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA9TTVK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYP.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2588719040","title":"Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588719040","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588719040?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:29","pubTimestamp":1764815349,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  said an independent data and safety monitoring board completed a planned review of the first group of patients treated in the phase 1/2 NEREID kidney transplant trial, which did not raise safety concerns for its CYP-001 therapy candidate, granting clearance to proceed to the second group, according to a Thursday Australian bourse filing.The first group of patients in the trial each received a single intravenous infusion of the candidate around six weeks after receiving a kidney transplant, in addition to standard treatment. There were no episodes of kidney transplant rejection in this group.The trial is evaluating CYP-001 as a potential treatment to reduce reliance on long-term immunosuppressant drugs in kidney transplant recipients. The second group in the trial will involve another three patients, each of whom will receive two infusions of CYP-001, in addition to standard treatment.The firm's shares jumped 10% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK4539","BK7508","CYP.AU","BK7067","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2585437297","title":"Cynata Therapeutics Completes Phase 3 SCUIpTOR Trial in Knee Osteoarthritis; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437297","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437297?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:52","pubTimestamp":1763956350,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  completed the final participant visits in its pivotal phase 3 SCUIpTOR trial of CYP-004 for knee osteoarthritis, marking the end of the two-year follow-up, according to a Monday filing with the Australian bourse.The University of Sydney will complete data monitoring and quality checks, with the trial results anticipated in the second quarter of 2026, the filing added.The company's shares rose around 6% in recent Monday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","CYP.AU","BK7501","BK7508","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2583457295","title":"ASX Stock Picks With Estimated Discounts Of Up To 39.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583457295","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583457295?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:04","pubTimestamp":1763060694,"startTime":"0","endTime":"0","summary":"The Australian market has experienced a mixed week, with positive developments failing to offset concerns about prolonged high interest rates and sector-specific challenges. In this environment, identifying undervalued stocks becomes crucial, as they may offer potential opportunities for investors looking to navigate the current economic climate.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/retail/asx-lov/lovisa-holdings-shares/news/asx-stock-picks-with-estimated-discounts-of-up-to-391","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/retail/asx-lov/lovisa-holdings-shares/news/asx-stock-picks-with-estimated-discounts-of-up-to-391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","NWH.AU","BK7067","XKO.AU","BK7128","BK7015","XJO.AU","CYP.AU","WJL.AU","XAO.AU","CSX.AU","IMM.AU","BK7508","BK7007","BK7062","BK7078","TLX.AU","SLC.AU","LOV.AU","GYG.AU","BK7137","BK7055","SYL.AU","BK7070","RPL.AU","BK7501","BET.AU","NXL.AU"],"gpt_icon":0},{"id":"2581792930","title":"Cynata Therapeutics Ltd-Cynata Receives $1.7M R&D Tax Incentive Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2581792930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581792930?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:14","pubTimestamp":1762305248,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE7KZHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CYP.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2580255089","title":"Cynata Therapeutics' Three Active Programs Expected to Deliver 'Major' Catalysts Over Next Quarters, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2580255089","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580255089?lang=en_us&edition=fundamental","pubTime":"2025-11-03 09:52","pubTimestamp":1762134736,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics  continued to advance its clinical pipeline, with three active programs expected to deliver major catalysts over several quarters, according to a Friday note by Euroz Hartleys.The research firm added that the opportunity for CYP remains as \"strong\" as ever, as last year the US Food and Drug Administration approved its first-ever mesenchymal stem cell  therapy, which was subsequently priced at about $1.55 million per patient.The research firm believes that the approval has established both regulatory and commercial precedents, which are \"very positive\" for the MSC sector.Euroz Hartleys has maintained a speculative buy rating on Cyanata Therapeutics with a price target of AU$0.90.The company's shares fell 2% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4575","BK7501","LENZ","BK4007","MSC","NPW.SI","BK4150","CYP.AU","BK6078","BK7508","BK4539","BK6507","BK7067"],"gpt_icon":0},{"id":"2579140481","title":"Cynata Therapeutics Ltd-September 2025 Quarterly Activity Report and Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2579140481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579140481?lang=en_us&edition=fundamental","pubTime":"2025-10-31 10:36","pubTimestamp":1761878184,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUEBYY3RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CYP.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2578868669","title":"When Will Cynata Therapeutics Limited (ASX:CYP) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578868669","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578868669?lang=en_us&edition=fundamental","pubTime":"2025-10-27 06:31","pubTimestamp":1761517900,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Cynata Therapeutics Limited's ( ASX:CYP ) business as it appears the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/when-will-cynata-therapeutics-limited-asxcyp-turn-a-profit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cyp/cynata-therapeutics-shares/news/when-will-cynata-therapeutics-limited-asxcyp-turn-a-profit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","CYP.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2577310212","title":"3 ASX Stocks That May Be Trading Below Estimated Value In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577310212","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577310212?lang=en_us&edition=fundamental","pubTime":"2025-10-23 03:04","pubTimestamp":1761159880,"startTime":"0","endTime":"0","summary":"As the Australian market experiences fluctuations driven by profit-taking and shifts in global economic sentiment, investors are closely watching sectors like Materials and Energy for opportunities. In this environment, identifying stocks that may be trading below their estimated value can be crucial for those looking to capitalize on potential market inefficiencies.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/3-asx-stocks-that-may-be-trading-below-estimated-value-in-oc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/3-asx-stocks-that-may-be-trading-below-estimated-value-in-oc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7002","RMC.AU","NWH.AU","CYP.AU","BK7067","MGH.AU","XAO.AU","BK7117","ART.AU","BK7160","BK7504","JHX.AU","BK7501","BK7055","BK7016","BK7126","LTR.AU","BK7123","BK7508","BK7505","BK7015","BK7044","XJO.AU","BK7115","FCL.AU","PNV.AU","BET.AU","DRO.AU","XKO.AU","SLC.AU","BK7078","ELD.AU","BK7095"],"gpt_icon":0},{"id":"2575317768","title":"ASX Stocks Priced Below Intrinsic Value Estimates Include Guzman y Gomez And Two More","url":"https://stock-news.laohu8.com/highlight/detail?id=2575317768","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575317768?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:04","pubTimestamp":1760555079,"startTime":"0","endTime":"0","summary":"The Australian stock market has shown resilience, with the ASX200 gaining 10% over the past ten months, despite a relatively uneventful September. Recent developments in critical minerals and healthcare have sparked investor interest, highlighting opportunities for stocks priced below their intrinsic value estimates. In this context, identifying undervalued stocks requires a keen understanding of market trends and potential catalysts like geopolitical shifts or sector-specific growth drivers.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-mgh/maas-group-holdings-shares/news/asx-stocks-priced-below-intrinsic-value-estimates-include-gu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-mgh/maas-group-holdings-shares/news/asx-stocks-priced-below-intrinsic-value-estimates-include-gu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XKO.AU","LTR.AU","BK7160","XAO.AU","BK7501","ART.AU","MGH.AU","RMC.AU","BK7002","BK7123","RKN.AU","BK7055","BK7044","XJO.AU","CCR.AU","GYG.AU","BK7015","BK7504","JHX.AU","SRG.AU","BK7067","BK7137","BK7508","BK7016","NWH.AU","SLC.AU","BK7095","CYP.AU"],"gpt_icon":0},{"id":"2575432220","title":"ASX Value Insights Duratec And Two More Stocks Possibly Below Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2575432220","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575432220?lang=en_us&edition=fundamental","pubTime":"2025-10-15 03:04","pubTimestamp":1760468672,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape, with materials stocks surging on the back of rising gold and rare earth prices while defence stocks dip following peace developments in the Middle East, investors are keenly observing sectors for potential opportunities. In such a fluctuating environment, identifying undervalued stocks like Duratec and others can offer promising prospects for those seeking to capitalize on discrepancies between current stock prices and perceived fair value.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-value-insights-duratec-and-two-more-stocks-possibly-belo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-value-insights-duratec-and-two-more-stocks-possibly-belo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CYP.AU","BK7508","BK7504","BK7007","BK7016","BK7067","RMC.AU","PNR.AU","XAO.AU","BK7095","BK7501","BK7104","CSX.AU","LOV.AU","LTR.AU","XJO.AU","BK7123","DUR.AU","EOS.AU","BK7115","CCR.AU","BK7015","IMM.AU","BK7160","BK7055","SLC.AU","BK7128","NWH.AU","XKO.AU"],"gpt_icon":0},{"id":"2574644906","title":"ASX Insights On Electro Optic Systems Holdings And 2 Other Stocks Priced Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2574644906","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574644906?lang=en_us&edition=fundamental","pubTime":"2025-10-09 03:08","pubTimestamp":1759950513,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of mixed performance, with the ASX ending flat midweek and US futures showing unreliable signals, investors are keenly observing sectors that might offer hidden value. In such an environment, identifying undervalued stocks like Electro Optic Systems Holdings can be crucial for those looking to capitalize on discrepancies between current prices and estimated intrinsic values.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-insights-on-electro-optic-systems-holdings-and-2-other-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-insights-on-electro-optic-systems-holdings-and-2-other-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","ART.AU","XKO.AU","XAO.AU","XJO.AU","SPZ.AU","BK7055","BK7016","CYP.AU","BK7115","BK7047","BK7084","BK7002","NWH.AU","BK7015","JHX.AU","EOS.AU","ELD.AU","BK7508","BK7505","RKN.AU","BK7067","SLC.AU","BK7044","BK7117","CSX.AU","RMC.AU","BK7123","BK7007","BK7160"],"gpt_icon":0},{"id":"2573985037","title":"ASX Value Stock Estimates Offering Opportunities In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573985037","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573985037?lang=en_us&edition=fundamental","pubTime":"2025-10-07 03:04","pubTimestamp":1759777474,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a slight pullback following a recent surge, investors are keenly observing how global factors like U.S. government actions and fluctuating commodity prices impact local indices. In this context, identifying undervalued stocks becomes crucial as they offer potential opportunities for growth amidst the current market volatility.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9021000-choice2-main-header/1585186684476","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9021000-choice2-main-header/1585186684476"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/telecom/asx-slc/superloop-shares/news/asx-value-stock-estimates-offering-opportunities-in-october","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/telecom/asx-slc/superloop-shares/news/asx-value-stock-estimates-offering-opportunities-in-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7117","CYP.AU","BK7501","BK7508","BK7160","SLC.AU","BK7007","BK7055","BK7505","PWH.AU","BK7067","BK7051","BK7016","NWH.AU","BK7123","CSX.AU","BK7015","CCR.AU","RMC.AU","ELD.AU","XJO.AU","BK7070","IMM.AU","WEB.AU","ART.AU","RKN.AU","BK7002"],"gpt_icon":0},{"id":"2573645996","title":"ASX Stocks That May Be Undervalued In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573645996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573645996?lang=en_us&edition=fundamental","pubTime":"2025-10-06 03:04","pubTimestamp":1759691067,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a slight pullback following a bullish surge, investors are keenly observing the ASX 200's movements amidst fluctuating global economic factors such as U.S. government shutdown concerns and rising gold prices. In this context, identifying undervalued stocks can be particularly appealing, as they may offer potential opportunities for growth in a market that is currently experiencing volatility and consolidation.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-nic/nickel-industries-shares/news/asx-stocks-that-may-be-undervalued-in-october-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-nic/nickel-industries-shares/news/asx-stocks-that-may-be-undervalued-in-october-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NIC.AU","BK7016","ART.AU","BK7123","RMC.AU","BK7501","BK7503","IMM.AU","BK7505","ELD.AU","BK7067","CSX.AU","NWH.AU","BK7055","CCR.AU","BK7095","CYP.AU","BK7002","BK7015","BK7007","BK7508","RKN.AU","IFM.AU","BK7160","SLC.AU","BK7117"],"gpt_icon":0},{"id":"2561450594","title":"BRIEF-Cynata Therapeutics Enters At-Market Subscription Agreement With Acuity Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2561450594","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561450594?lang=en_us&edition=fundamental","pubTime":"2025-08-22 10:01","pubTimestamp":1755828088,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Enters At-Market Subscription Agreement With Acuity CapitalAug 22  - Cynata Therapeutics Ltd CYP.AX:ENTERED INTO AN AT--MARKET SUBSCRIPTION AGREEMENT WITH ACUITY CAPITALDEAL PROVIDES CO WITH UP TO A$7.5 MILLION OF STANDBY EQUITY CAPITAL OVER COMING 5 YEARSFurther company coverage: CYP.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nFWN3UD16B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CYP.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2561412914","title":"Cynata Therapeutics Ltd -  Entered Into an at--Market Subscription Agreement With Acuity Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2561412914","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561412914?lang=en_us&edition=fundamental","pubTime":"2025-08-22 07:19","pubTimestamp":1755818345,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nFWN3UD16B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CYP.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}